The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Dominick Passanante of Panasonic Connect breaks down the innovations behind TOUGHBOOK and why rugged tech is more relevant than ever in today's mobile workforce
Voya Financial CEO Heather Lavallee marks 10 years of Voya Cares, spotlighting research and expanding financial access for Americans with disabilities.
When Treasury Secretary Scott Bessent (above) and Fed chair Jay Powell jointly summon America’s top bankers to a meeting in Washington, you know it’s big.
Kim Crawford Goodman, CEO of Smarsh, breaks down how financial firms are scaling AI while managing compliance, risk, and regulation in a changing landscape.
Elizabeth Renter, Senior Economist at NerdWallet, breaks down how inflation and oil price shocks are driving higher costs and squeezing consumers today.
